Novo Nordisk launches Wegovy pill in the U.S. at $149 a month for cash payers

Novo Nordisk launched the Wegovy pill in the United States on Jan. 5, 2026, making it the first oral GLP-1 medicine approved for weight loss. The starting 1.5 mg dose costs $149 a month for people paying cash, or about $5 a day, the company said ^[1][6].

Wegovy (semaglutide) tablets are taken once a day. The FDA approved them on Dec. 22, 2025, and they come in four strengths: 1.5 mg, 4 mg, 9 mg and 25 mg, with 25 mg as the maximum maintenance dose ^[1][6]. Novo says the pill is available at more than 70,000 U.S. pharmacies, including CVS and Costco, and through telehealth providers including Ro, LifeMD and Weight Watchers, GoodRx, and Novo Nordisk's own NovoCare Pharmacy ^[1][4][6].

What the pill costs

For cash payers, Novo set the 1.5 mg starter dose at $149 per month. The 4 mg dose is also $149 per month through April 15, 2026, after which it rises to $199 per month. The 9 mg and 25 mg doses are $299 per month ^[1][4][6]. Novo's published price guide lists 4 mg at $199 as the standard self-pay price, the level it reaches after the introductory period ^[3].

People with commercial insurance can pay as little as $25 per month using the Wegovy savings offer, which caps savings at $100 per month. Government beneficiaries are excluded from that offer ^[3][6]. Novo Nordisk says it can modify or cancel these programs at any time ^[3].

What the trial showed

The approval is based on the OASIS 4 phase 3 trial, a 64-week study of 307 adults with obesity, or with overweight plus at least one weight-related condition, none of whom had diabetes ^[6]. Participants who took the 25 mg pill along with a reduced-calorie diet and exercise lost an average of about 16.6% of body weight if all patients stayed on treatment, compared with about 2.7% for placebo. Counting all patients regardless of whether they stayed on treatment, average weight loss was 13.6% versus 2.4% ^[1][6].

In the trial, 76% of people taking the pill lost at least 5% of their body weight, compared with 31% on placebo. Baseline body weights were 235 pounds for the pill group and 231 pounds for placebo ^[6]. The most common adverse reactions were nausea, diarrhea and vomiting, similar to those seen with injectable Wegovy 2.4 mg ^[6].

Wegovy pill is also cleared to reduce the risk of major adverse cardiovascular events such as death, heart attack or stroke in adults with overweight or obesity and established cardiovascular disease ^[1][6].

Why it matters for patients

The pill gives adults who want to avoid injections a semaglutide option that needs no refrigeration, which Novo has said could widen access ^[1]. Its cash price also sits below what uninsured patients pay for the injectable: after a November pricing deal with the White House, Novo cut self-pay prices for injectable Wegovy and for all but the 2 mg dose of Ozempic to $349 a month, down from $499 ^[1].

The $25 monthly figure depends on having commercial insurance and using the savings offer; it does not apply to people on government plans such as Medicare or Medicaid ^[3][6]. Whether a given insurance plan covers the pill, and what prior authorization it requires, has not been reported.

Because Wegovy contains semaglutide, it should not be used with other semaglutide products or other GLP-1 receptor agonist medicines ^[5]. Novo says it is directing patients toward FDA-approved medicines and away from compounded alternatives ^[6]. It is not known if the tablets are safe and effective for people under 18 ^[5].

What happens next

April 15, 2026 is the date Novo has given for the 4 mg cash price to move from $149 to $199 a month ^[1][4][6]. Eli Lilly's oral obesity candidate orforglipron is under FDA review, so Novo is launching its pill with a head start in the oral GLP-1 market ^[1]. Novo has said production of the pill was already "well underway" in North Carolina ahead of the launch ^[1]. Semaglutide was first approved as an oral tablet in 2019, as the type 2 diabetes medicine Rybelsus ^[1].